Furthermore, they discovered that gefitinib did not inhibit the Phosphoinositide 3-kinase (PI3K)/AKT pathway in PC9-CSCs.These results suggest that the miR-128/c-met axis improves gefitinib susceptibility in lung cancer stem cells by inhibiting the PI3K/AKT axis. Here, MET is linked to lung carcinoma.